Reye's Syndrome

1. Clinical Overview

Summary

Reye's Syndrome (RS) is a rare, life-threatening acute non-inflammatory encephalopathy associated with microvesicular fatty degeneration of the viscera, particularly affecting the liver and brain. First described by R.D.K. Reye in 1963 in Australian children, the syndrome is classically triggered by the use of salicylates (aspirin) during or shortly after viral infections, most commonly influenza B or varicella (chickenpox), in children and adolescents. [1,2]

The pathognomonic triad consists of:

1. Acute encephalopathy with altered consciousness
2. Hepatic dysfunction without hyperbilirubinaemia (non-icteric hepatopathy)
3. Elevation of serum transaminases and ammonia

Since the epidemiological association between aspirin use in febrile children and Reye's Syndrome was established in the 1980s, public health warnings led to the contraindication of aspirin in children under 16 years. This resulted in a dramatic decline in incidence from approximately 0.5-1.0 per 100,000 children in the early 1980s to less than 0.1 per million currently. [3,4] The syndrome is now considered a diagnosis of exclusion, with most contemporary "Reye-like" presentations representing previously undiagnosed inborn errors of metabolism (IEM), particularly fatty acid oxidation disorders and urea cycle defects. [5]

Historical Context

The syndrome was simultaneously described by R.D.K. Reye in Australia and G. Johnson in the United States in 1963, initially termed "encephalopathy with fatty degeneration of the viscera." The condition gained widespread recognition in the 1970s when clusters of cases were reported following influenza outbreaks. The breakthrough epidemiological link to aspirin came from CDC case-control studies in the early 1980s, leading to regulatory warnings and labelling changes. [6,7]

Clinical Pearls

Modern Diagnostic Paradigm: In the contemporary era, a child presenting with classical "Reye's Syndrome" features almost certainly harbours an underlying metabolic disorder. The most common mimics include MCAD deficiency (medium-chain acyl-CoA dehydrogenase deficiency), OTC deficiency (ornithine transcarbamylase deficiency), and other fatty acid oxidation disorders. These conditions are unmasked by the metabolic stress of intercurrent viral illness and replicate the RS phenotype. [5,8]

Anicteric Hepatopathy: The pathognomonic feature distinguishing RS from viral hepatitis is liver dysfunction (coagulopathy, elevated transaminases, hyperammonaemia) without jaundice. Serum bilirubin remains normal or only minimally elevated (< 50 µmol/L). The presence of significant hyperbilirubinaemia should prompt investigation for alternative diagnoses including viral hepatitis, drug-induced liver injury, or biliary obstruction. [9]

The Kawasaki Exception: Kawasaki disease remains the only paediatric indication for high-dose aspirin therapy in contemporary practice (80-100 mg/kg/day in acute phase, then 3-5 mg/kg/day for antiplatelet effect). Children receiving aspirin for Kawasaki disease are at theoretical risk of RS if they contract influenza or varicella. Current guidelines recommend annual influenza vaccination and varicella vaccination for these patients to mitigate risk. [10]

Two-Hit Hypothesis: The current mechanistic model proposes RS results from a "two-hit" insult: (1) viral infection inducing metabolic stress and mitochondrial dysfunction, combined with (2) salicylate exposure causing further mitochondrial injury and inhibition of β-oxidation. This synergistic toxicity overwhelms cellular energetics in susceptible individuals. [11]

---

2. Epidemiology

Historical Incidence

During the peak incidence in 1979-1980, the United States documented 555 cases annually (approximately 0.5-1.0 per 100,000 children). Following public health warnings about aspirin use in 1982-1986 and subsequent FDA regulatory action requiring warning labels, incidence plummeted dramatically. [3,4]

Current Epidemiology

• Incidence: Less than 0.1 cases per million children annually in developed countries. In the UK, fewer than 5 confirmed cases are reported per year.
• Age Distribution: Historically peaked at 4-12 years (mean 6-8 years), with 80-90% of cases occurring between ages 4-16 years. Cases in children under 1 year were rare and should raise suspicion for metabolic disorders.
• Seasonal Pattern: Winter and spring predominance, correlating temporally with influenza A and B outbreaks. A secondary smaller peak occurred in late spring associated with varicella epidemics.
• Geographic Variation: Higher reported incidence in rural compared to urban areas (unclear whether representing true prevalence difference or ascertainment bias).

Demographics

• Sex Distribution: Slight male predominance (male:female ratio approximately 1.2-1.5:1) in most case series.
• Ethnicity: No consistent ethnic predisposition identified, though some studies suggested higher incidence in Caucasian populations (may reflect healthcare access bias).

Risk Factors

Infectious Triggers

• Influenza B (~25-40% of cases): Strongest association, particularly during epidemic years
• Influenza A (~20-30%): Secondary most common
• Varicella zoster virus (~15-20%): Higher case-fatality rate compared to influenza-associated cases
• Other viruses (rare): Adenovirus, enteroviruses, Epstein-Barr virus, parainfluenza, rotavirus

Pharmacological Risk Factors

• Salicylates: Aspirin (acetylsalicylic acid) is the primary pharmaceutical risk factor. Dose-response relationship demonstrated in case-control studies (odds ratio 10-40 for aspirin exposure during viral illness).
• Salicylate-containing products: Bismuth subsalicylate (Pepto-Bismol), oil of wintergreen, some topical preparations
• Herbal preparations: Willow bark extract (natural source of salicin, metabolized to salicylic acid)

Host Factors

• Possible genetic susceptibility: Some evidence suggests polymorphisms in genes encoding mitochondrial enzymes may increase susceptibility, though no consistent genetic markers identified.
• Nutritional status: Potential association with marginal carnitine status (unproven).

Temporal Trends and Current Context

The dramatic decline in RS incidence following aspirin warnings represents one of the most successful pharmaceutical-epidemiological interventions in paediatric medicine. Contemporary "sporadic" cases warrant aggressive investigation for IEM, with metabolic screening identifying an alternative diagnosis in 60-80% of Reye-like presentations. [5,12]

---

3. Pathophysiology

Molecular and Cellular Mechanisms

Reye's Syndrome results from acute, severe mitochondrial dysfunction affecting multiple organs, with predominant involvement of hepatocytes and astrocytes. The pathophysiology represents a complex interplay of viral-induced metabolic stress and salicylate-mediated mitochondrial toxicity.

Mitochondrial Injury Cascade

1. Dual-Hit Mitochondrial Insult

The "two-hit" hypothesis proposes sequential or synergistic insults: [11,13]

• First Hit (Viral Infection):

  • Viral replication and immune response induce interferon-γ and other cytokines
  • Cytokines trigger oxidative stress and mitochondrial membrane perturbation
  • Increased metabolic demands from fever and immune activation stress mitochondrial ATP production

• Second Hit (Salicylate Exposure):

  • Salicylates uncouple oxidative phosphorylation, disrupting the proton gradient across the inner mitochondrial membrane
  • Inhibition of mitochondrial enzymes including carnitine palmitoyltransferase-1 (CPT-1)
  • Disruption of β-oxidation of long-chain and medium-chain fatty acids
  • Direct mitochondrial membrane damage

2. Hepatic Consequences

The liver bears the brunt of mitochondrial dysfunction due to high metabolic activity and salicylate metabolism:

• Microvesicular Steatosis:

  • Impaired β-oxidation leads to cytoplasmic accumulation of free fatty acids
  • Formation of characteristic small lipid droplets (< 1 µm diameter) within hepatocytes, distributed throughout lobules
  • Nucleus remains central (distinguishing from macrovesicular steatosis where nucleus is displaced)
  • Preserved hepatocyte architecture initially (no significant necrosis or inflammation)

• Hypoglycaemia:

  • Depletion of hepatic glycogen stores (visualized as absent glycogen on PAS staining)
  • Impaired gluconeogenesis due to mitochondrial dysfunction and depleted TCA cycle intermediates
  • Inhibition of pyruvate carboxylase and phosphoenolpyruvate carboxykinase
  • Particularly problematic in children with limited glycogen reserves

• Hyperammonaemia:

  • Urea cycle enzymes (carbamyl phosphate synthetase, ornithine transcarbamylase) are mitochondrial and energy-dependent
  • ATP depletion impairs conversion of ammonia to urea
  • Serum ammonia typically rises 3-10 fold above normal (often 100 µmol/L, occasionally 300 µmol/L)
  • Ammonia levels correlate with neurological severity and prognosis

• Coagulopathy:

  • Reduced hepatic synthesis of vitamin K-dependent clotting factors (II, VII, IX, X)
  • Synthesis impairment due to energy deficiency rather than structural damage
  • Prolongation of PT and APTT (PT typically more affected initially)
  • Factor V may be reduced (helps distinguish from vitamin K deficiency)

3. Cerebral Consequences

Brain injury in RS is primarily metabolic and oedematous rather than inflammatory:

• Astrocyte Swelling:

  • Ammonia detoxification in brain occurs via glutamine synthetase in astrocytes
  • Conversion of glutamate + ammonia → glutamine is ATP-dependent
  • Intracellular glutamine accumulation creates osmotic gradient
  • Astrocyte swelling ("Alzheimer type II astrocytes" on histology)

• Cerebral Oedema:

  • Initially cytotoxic (cellular swelling) rather than vasogenic
  • Later progression to vasogenic oedema as blood-brain barrier integrity compromised
  • Free fatty acids and ammonia contribute to endothelial dysfunction
  • Diffuse brain swelling with obliteration of ventricles and sulci on imaging

• Raised Intracranial Pressure (ICP):

  • Progressive increase in ICP parallels worsening encephalopathy
  • ICP 20-25 mmHg associated with risk of herniation
  • Cerebral perfusion pressure (CPP = MAP - ICP) becomes critically low
  • "Herniation syndromes: uncal herniation (CN III palsy, ipsilateral pupil dilation) or central herniation (rostral-caudal deterioration)"

Systemic Manifestations

• Pancreatitis (10-15% of cases): Likely reflects pancreatic acinar cell mitochondrial dysfunction
• Myopathy: Skeletal muscle may show fatty infiltration; elevated creatine kinase in some cases
• Renal involvement: Usually secondary to hypotension/hypoperfusion rather than direct tubular toxicity

Pathological Findings

Macroscopic Pathology:

• Liver: Enlarged, pale, yellow-tan colour (fatty infiltration); firm consistency; no necrosis or inflammation visible
• Brain: Swollen, flattened gyri, narrowed sulci, slit-like ventricles; no focal lesions

Microscopic Pathology:

• Liver: Pan-lobular microvesicular steatosis (oil red O stain positive on frozen sections); minimal inflammation; preserved reticulin framework; electron microscopy shows pleomorphic, swollen mitochondria with disrupted cristae
• Brain: Neuronal oedema without inflammation; astrocyte swelling; no necrosis initially (unless prolonged ischaemia from herniation)

---

4. Clinical Presentation

The Biphasic Clinical Course

Reye's Syndrome characteristically presents with a biphasic pattern: initial viral illness followed by apparent recovery, then sudden deterioration with vomiting and encephalopathy. This pattern is crucial for diagnosis and distinguishing from primary CNS infection.

Phase 1: Viral Prodrome (Day 0-5)

• Typical viral upper respiratory tract infection or varicella
• Fever, coryza, cough, malaise (if influenza)
• Rash and vesicular lesions (if varicella)
• Managed symptomatically at home or primary care
• Aspirin exposure during this phase (key historical feature)

Phase 2: Apparent Recovery (Day 3-5)

• Fever defervescence
• Improvement in respiratory or dermatological symptoms
• Child seems to be getting better
• Duration: 12-72 hours typically

Phase 3: Acute Deterioration (Day 5-8 post-viral onset)

This phase marks the onset of RS proper and requires immediate medical attention.

Lovejoy Clinical Staging System

The Lovejoy staging system (1974) remains the standard classification for RS severity and guides management decisions. Progression through stages can be rapid (hours) or protracted (days). [14]

Stage I (Early Encephalopathy)

• Vomiting: Profuse, protracted, intractable ("pernicious vomiting")
• Lethargy: Sleepiness beyond normal post-viral fatigue
• Laboratory findings: Mild hyperammonaemia (50-100 µmol/L), elevated transaminases (3-10x normal)
• Mental status: Responds appropriately to verbal commands, though may be drowsy
• EEG: Normal or mild slowing
• Prognosis: Excellent if recognised at this stage; nearly 100% survival with supportive care

Stage II (Moderate Encephalopathy)

• Confusion and disorientation: Does not recognise familiar people or places
• Combativeness: Aggressive behaviour, irritability, agitation
• Delirium: Hallucinations, inappropriate verbal responses
• Hyperventilation: Tachypnoea (respiratory alkalosis)
• Hyperreflexia: Brisk deep tendon reflexes
• Pupils: Normal or sluggish response
• Laboratory findings: Ammonia 100-200 µmol/L, prolonged PT/APTT
• Prognosis: 90-95% survival with intensive management

Stage III (Severe Encephalopathy - Decorticate)

• Coma: Unresponsive to verbal stimuli
• Decorticate posturing: Flexion of upper limbs, extension of lower limbs (indicates cortical/subcortical dysfunction)
• Pupils: Sluggish or poorly reactive to light
• Intact oculocephalic reflexes (doll's eyes)
• Intact oculovestibular reflexes (caloric testing)
• Laboratory findings: Ammonia 200 µmol/L, significant coagulopathy
• Prognosis: 60-70% survival; neurological sequelae common in survivors

Stage IV (Deeper Coma - Decerebrate)

• Deeper coma: No purposeful response to painful stimuli
• Decerebrate posturing: Extension of all four limbs (indicates midbrain dysfunction)
• Fixed dilated pupils: Loss of pupillary light reflex
• Loss of oculocephalic and oculovestibular reflexes: Indicates brainstem dysfunction
• Dysconjugate eye movements
• Prognosis: 40-50% survival; high rate of severe neurological sequelae

Stage V (Seizures and Profound Coma)

• Seizures: Generalised tonic-clonic or subtle seizures
• Flaccidity: Loss of all motor tone (indicates medullary dysfunction)
• Loss of deep tendon reflexes
• Respiratory failure: Apnoea or irregular breathing (requires mechanical ventilation)
• Absent pupillary responses
• ICP typically 40 mmHg: Cerebral herniation imminent or occurred
• Prognosis: < 20% survival; survivors usually have severe permanent neurological disability

Key Clinical Features by System

Neurological

• Altered consciousness: Ranging from lethargy to coma (universal feature)
• Behaviour changes: Irritability, aggression, personality change
• Seizures: 10-30% of patients, more common in advanced stages
• Focal neurological signs: Rare unless herniation occurs (then asymmetric pupils, hemiparesis)

Gastrointestinal

• Vomiting: Profuse, persistent, not relieved by anti-emetics (in 90% of cases)
• Hepatomegaly: Present in 40-60%, usually smooth and non-tender
• Absence of jaundice: Pathognomonic (if jaundice present, consider alternative diagnosis)
• Abdominal pain: Occasionally reported

Respiratory

• Hyperventilation: Respiratory alkalosis in stages I-III (due to ammonia stimulating respiratory centre)
• Respiratory failure: Stages IV-V (requires mechanical ventilation)

Cardiovascular

• Tachycardia: Proportional to degree of distress
• Hypotension: Late sign indicating cardiovascular compromise (poor prognosis)
• Arrhythmias: Rare unless severe metabolic derangement

Atypical Presentations

• Neonates and infants: Extremely rare; should trigger immediate metabolic investigation for IEM
• Adolescents and adults: Occasionally reported; mortality may be higher
• Reye-like syndrome without aspirin exposure: Strongly suggests underlying metabolic disorder

---

5. Clinical Examination

Systematic Examination Approach

A focused yet comprehensive examination is essential, prioritising neurological assessment and seeking features distinguishing RS from alternative diagnoses.

General Appearance

• Level of consciousness: AVPU or Glasgow Coma Scale (GCS)
• Hydration status: Assess for dehydration from vomiting (skin turgor, mucous membranes, capillary refill)
• Jaundice: Absence is expected; presence of scleral icterus or jaundice should prompt reconsideration of diagnosis
• Fever: Usually absent in RS proper (suggests ongoing infection or alternative diagnosis)
• Rash: Look for varicella lesions (vesicles, crusted lesions at various stages) or healing chickenpox scars

Neurological Examination

Mental Status:

• Orientation to person, place, time
• Appropriateness of responses
• Behaviour: combative, agitated, or withdrawn

Cranial Nerves:

• Pupils: Size, symmetry, reactivity (critical for detecting herniation)
  • "Equal and reactive: Stages I-II"
  • "Sluggish: Stage III"
  • "Fixed dilated (especially unilateral): Stage IV and impending uncal herniation"
• Oculocephalic reflex (doll's eyes): Assess if comatose
• Fundoscopy: Look for papilloedema (raised ICP), though often absent acutely

Motor:

• Tone: Normal → increased → flaccid (as stages progress)
• Posturing:
  • Spontaneous or in response to painful stimulus
  • "Decorticate (Stage III): Arms flexed, legs extended"
  • "Decerebrate (Stage IV): All limbs extended"
  • "Flaccid (Stage V): No motor response"

Reflexes:

• Deep tendon reflexes: Normal → hyperreflexia (Stage II) → diminished/absent (Stage V)
• Plantar reflex: Upgoing (Babinski sign) indicates upper motor neuron dysfunction

Abdominal Examination

• Hepatomegaly: Palpate for liver edge (present in 40-60%)
  • "Characteristics: Smooth, firm, non-tender, spans 2-6 cm below costal margin"
  • In advanced encephalopathy, liver may decrease in size (acute atrophy)
• Splenomegaly: Typically absent (if present, consider alternative diagnosis)
• Ascites: Not a feature of RS
• Tenderness: Mild epigastric tenderness possible; severe pain unusual

Respiratory Examination

• Respiratory rate: Tachypnoea (hyperventilation) in stages I-III
• Pattern: Regular hyperventilation vs irregular/apnoeic (late stages)
• Chest auscultation: Usually clear (unless aspiration pneumonia)

Cardiovascular Examination

• Heart rate: Tachycardia
• Blood pressure: Usually maintained until late stages
• Capillary refill: Assess perfusion

Skin Examination

• Varicella lesions: Various stages (macules, papules, vesicles, crusts)
• Bruising/petechiae: May indicate coagulopathy
• Stigmata of chronic liver disease: Absent (distinguishes from chronic liver conditions)

Red Flag Examination Findings

---

6. Investigations

A comprehensive, systematic investigative approach serves three purposes: (1) confirm RS diagnosis, (2) exclude mimicking conditions (especially IEM), and (3) guide management and prognostication.

Immediate Bedside Investigations

Blood Glucose (Capillary and Laboratory)

• Critical first-line test: Hypoglycaemia common and life-threatening
• Typical finding: < 3.0 mmol/L in 40-60% of cases
• Mechanism: Depleted glycogen stores + impaired gluconeogenesis
• Action: Immediate correction with IV dextrose (2-5 mL/kg of 10% dextrose bolus, then continuous infusion)

Arterial Blood Gas

• Typical findings:
  • "Stages I-III: Respiratory alkalosis (pH 7.45-7.55, low PaCO₂) from hyperventilation"
  • "Advanced stages: Mixed respiratory and metabolic acidosis (lactate elevation, respiratory failure)"
• Lactate: May be elevated (reflects mitochondrial dysfunction and tissue hypoperfusion)

Essential Laboratory Investigations

Liver Function Tests

Coagulation Profile

• PT/INR: Prolonged (often 1.5-3x normal)
• APTT: Prolonged
• Fibrinogen: Usually normal or elevated (acute phase reactant)
• Factor V: May be reduced (helps distinguish from isolated vitamin K deficiency)
• Interpretation: Reflects impaired hepatic synthetic function, NOT consumptive coagulopathy (DIC)

Ammonia

• Critical diagnostic and prognostic marker
• Normal: < 30-40 µmol/L (age-dependent)
• Typical RS: 50-300 µmol/L (3-10x elevation)
• Correlation: Higher levels associated with worse neurological stage and prognosis
• Technical note: Specimen must be on ice and analysed within 15-30 minutes (ammonia rises in specimen over time)

Electrolytes and Renal Function

• Sodium, potassium: Usually normal unless vomiting-induced losses or inappropriate fluid resuscitation
• Urea: May be low (impaired urea synthesis)
• Creatinine: Usually normal unless hypoperfusion/acute kidney injury
• Bicarbonate: Low if metabolic acidosis develops

Other Biochemistry

• Creatine kinase (CK): May be elevated (myopathy, rhabdomyolysis)
• Lipase/Amylase: Elevated if pancreatitis complicates RS (10-15% of cases)
• Phosphate: May be low (refeeding once dextrose started)

Metabolic Screening (Mandatory in Contemporary Practice)

Given that most "Reye-like" presentations in the post-aspirin era represent IEM, comprehensive metabolic screening is essential and should not be delayed. [5,12]

Plasma Amino Acids

• Purpose: Detect urea cycle disorders, organic acidaemias
• Key findings in mimics:
  • "Elevated citrulline, arginine: urea cycle defects"
  • "Elevated leucine, isoleucine, valine: maple syrup urine disease"

Urine Organic Acids (collect before significant dextrose given)

• Purpose: Identify organic acidaemias, fatty acid oxidation disorders
• Key findings:
  • "Dicarboxylic aciduria: MCAD deficiency, LCHAD deficiency"
  • 3-hydroxy-3-methylglutaric acid: HMG-CoA lyase deficiency

Acylcarnitine Profile

• Purpose: Screen for fatty acid oxidation disorders
• Key findings:
  • "Elevated C6-C10 acylcarnitines: MCAD deficiency"
  • "Elevated C14-C18: LCHAD or VLCAD deficiency"

Free Fatty Acids and Ketones

• Typical RS: Elevated free fatty acids, inappropriately low ketones (impaired β-oxidation)
• Helps distinguish from diabetic ketoacidosis

Carnitine Levels

• Total and free carnitine: May be low (primary or secondary deficiency)

Microbiological Investigations

Viral Testing

• Influenza PCR (nasopharyngeal swab): Confirm influenza A or B
• Varicella PCR or serology: If history of recent chickenpox
• Other viral PCRs: Consider depending on prodromal illness

Blood Cultures

• Purpose: Exclude bacterial sepsis (mandatory in encephalopathic child)

Lumbar Puncture (if safe to perform)

• Indications: Exclude meningoencephalitis
• Contraindications: Raised ICP (papilloedema, focal neurology, reduced GCS), coagulopathy
• Typical RS CSF findings:
  • Normal cell count (WCC < 5/mm³)
  • Normal protein (or mildly elevated to 0.5-0.8 g/L)
  • "Normal glucose (CSF:blood ratio 0.6)"
  • Opening pressure may be elevated
• Interpretation: Normal CSF distinguishes RS from viral meningoencephalitis

Imaging

CT Head (Non-Contrast)

• Indications: Altered consciousness, focal neurology, suspected raised ICP
• Typical findings:
  • "Cerebral oedema: Loss of grey-white differentiation, compressed ventricles, effaced sulci"
  • "No focal lesions: Absence of haemorrhage, infarction, mass"
  • "Small ventricles: Indicates diffuse brain swelling"
• Later stages: May see evidence of herniation (tonsillar descent, uncal herniation)

MRI Brain (if stable enough)

• More sensitive than CT for early cytotoxic oedema
• Findings:
  • Restricted diffusion on DWI (cytotoxic oedema)
  • T2/FLAIR hyperintensity in white matter
  • May show basal ganglia or thalamic involvement

Abdominal Ultrasound

• Findings:
  • Hepatomegaly with increased echogenicity (fatty infiltration)
  • Normal biliary tree
• Purpose: Exclude structural liver or biliary pathology

Specialised Investigations

Liver Biopsy (Rarely Performed in Acute Setting)

• Indications: Diagnostic uncertainty, need for definitive diagnosis post-mortem
• Contraindications: Coagulopathy (must correct first), clinical instability
• Typical findings:
  • "Microvesicular steatosis: Small lipid droplets (< 1 µm) throughout cytoplasm, nucleus remains central"
  • Pan-lobular distribution
  • Minimal inflammation
  • Preserved reticulin framework
  • "Electron microscopy: Swollen, pleomorphic mitochondria with disrupted cristae"

EEG (Electroencephalography)

• Indications: Suspected seizures, prognostic information
• Typical findings:
  • "Stages I-II: Normal or mild diffuse slowing"
  • "Stages III-IV: Moderate to severe diffuse slowing"
  • "Stage V: Burst suppression or isoelectric (extremely poor prognosis)"

ICP Monitoring (if PICU available)

• Indications: Stage III or higher in specialist centres
• Target: Maintain ICP < 20 mmHg and CPP 50 mmHg
• Methods: Intraventricular catheter (gold standard) or intraparenchymal monitor

Genetic Testing (Post-Acute Phase or Family Screening)

If IEM suspected:

• Molecular genetic testing: Specific gene panels for fatty acid oxidation disorders, urea cycle defects
• Enzymatic assays: Cultured fibroblasts or lymphocytes
• Family screening: Siblings for carrier status (autosomal recessive disorders)

---

7. Differential Diagnosis

In contemporary practice, RS is a diagnosis of exclusion. The differential is broad and includes metabolic, infectious, toxic, and structural causes of acute encephalopathy with hepatic dysfunction.

Inborn Errors of Metabolism (Most Important in Modern Context)

Medium-Chain Acyl-CoA Dehydrogenase (MCAD) Deficiency

• Most common fatty acid oxidation disorder mimicking RS
• Mechanism: Impaired β-oxidation of C6-C12 fatty acids
• Triggers: Fasting, intercurrent illness
• Features: Hypoketotic hypoglycaemia, elevated dicarboxylic acids in urine, elevated C6-C10 acylcarnitines
• Distinguishing features: May have family history, recurrent episodes, no aspirin exposure
• Management: Avoid fasting, cornstarch supplementation, acute glucose therapy
• Prognosis: Excellent if recognised; preventable mortality

Ornithine Transcarbamylase (OTC) Deficiency

• Most common urea cycle disorder
• X-linked inheritance: Males severely affected, heterozygous females may present in adolescence
• Features: Hyperammonaemia (300 µmol/L common), low citrulline, elevated urinary orotic acid
• Distinguishing features: May present without preceding viral illness, protein ingestion may trigger
• Management: Protein restriction, ammonia scavengers (sodium benzoate, sodium phenylbutyrate), haemodialysis

Other Fatty Acid Oxidation Disorders

• Long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) deficiency
• Very long-chain acyl-CoA dehydrogenase (VLCAD) deficiency
• Carnitine palmitoyltransferase (CPT) I or II deficiency

Other Urea Cycle Disorders

• Citrullinaemia, argininosuccinic aciduria, carbamoyl phosphate synthetase deficiency

Infectious Causes

Viral Encephalitis

• Herpes simplex virus (HSV): Temporal lobe predilection on MRI, CSF pleocytosis, PCR positive
• Enteroviruses: Summer/autumn seasonality, CSF pleocytosis
• Features distinguishing from RS: CSF abnormalities (pleocytosis, elevated protein), focal neurological signs, MRI abnormalities

Bacterial Meningoencephalitis

• Features: Fever, CSF pleocytosis (neutrophilic), positive culture/PCR
• Gram stain: May reveal organism

Sepsis with Encephalopathy

• Features: Fever, haemodynamic instability, positive blood cultures, multi-organ involvement

Toxic/Pharmacological Causes

Valproate Hepatotoxicity

• Mechanism: Inhibition of β-oxidation (mimics RS closely)
• Features: Hyperammonaemia, hepatotoxicity, history of valproate use
• Distinguishing feature: Drug history

Paracetamol (Acetaminophen) Overdose

• Features: Jaundice common, very high transaminases (3000-10,000), detectable paracetamol level
• Distinguishing feature: Jaundice, history of ingestion

Aspirin Overdose (Salicylism)

• Features: Respiratory alkalosis followed by metabolic acidosis, tinnitus, detectable salicylate levels
• Distinguishing feature: Very high salicylate level (300 mg/L), different acid-base pattern

Hepatic Causes

Acute Viral Hepatitis

• Hepatitis A, B, C, E: Hepatitis A most common in children
• Features: Jaundice (distinguishes from RS), elevated bilirubin, positive serology
• Encephalopathy: Only in severe acute liver failure

Wilson Disease

• Age: Usually 5 years
• Features: Kayser-Fleischer rings, low ceruloplasmin, elevated urinary copper, haemolytic anaemia
• Fulminant presentation: Haemolysis + liver failure (AST/ALT ratio 2.2 characteristic)

Neurological Causes

Intracranial Haemorrhage or Mass Lesion

• Features: Focal neurological signs, CT/MRI shows lesion
• Causes: Trauma, vascular malformation, tumour

Acute Disseminated Encephalomyelitis (ADEM)

• Features: Post-infectious demyelination, multifocal neurological signs, MRI white matter lesions

Other Metabolic Causes

Diabetic Ketoacidosis

• Features: Hyperglycaemia (not hypoglycaemia), ketonuria, metabolic acidosis, known diabetes

Hypoglycaemic Encephalopathy (other causes)

• Insulinoma, adrenal insufficiency, glycogen storage disorders

---

8. Management

RS management is entirely supportive with the primary goals of (1) maintaining metabolic homeostasis, (2) managing cerebral oedema and ICP, and (3) preventing complications. There is no specific antidote or disease-modifying therapy. Early recognition and aggressive supportive care have dramatically improved survival from ~50% historically to 80% in contemporary series. [15]

Initial Assessment and Resuscitation (ABCDE Approach)

Airway

• Assessment: Patency, gag reflex, ability to protect airway
• Intervention:
  • "GCS ≤8 or rapid deterioration: Endotracheal intubation"
  • Consider intubation prophylactically in Stage III to allow controlled ventilation and ICP management
  • Avoid ketamine (may raise ICP); use propofol or thiopental

Breathing

• Assessment: Respiratory rate, pattern, oxygen saturation
• Intervention:
  • Oxygen to maintain SpO₂ 94%
  • "If intubated: Target normocapnia (PaCO₂ 4.5-5.0 kPa); avoid hypocapnia (< 4.0 kPa) as may cause cerebral ischaemia despite reducing ICP"
  • Monitor arterial blood gases

Circulation

• Assessment: Heart rate, blood pressure, capillary refill, urine output
• Intervention:
  • Secure two large-bore IV cannulae
  • Fluid resuscitation if hypovolaemic (10-20 mL/kg 0.9% saline bolus)
  • "Caution: Avoid fluid overload (exacerbates cerebral oedema); aim euvolaemia"
  • Maintain MAP to ensure adequate CPP (CPP = MAP - ICP; target CPP 50 mmHg)

Disability (Neurological)

• Assessment: GCS, pupil size and reactivity, posturing
• Intervention: Frequent reassessment (every 15-30 minutes initially)

Exposure

• Assessment: Temperature, rashes, signs of trauma

Specific Metabolic Management

Hypoglycaemia Correction (Priority #1)

• Immediate:
  • Bolus 2-5 mL/kg of 10% dextrose IV (avoid 50% dextrose in children - osmotic injury risk)
  • Recheck glucose after 10-15 minutes
• Maintenance:
  • Continuous IV 10% dextrose at 1.5-2x maintenance fluid rate (e.g., 100-150 mL/kg/day for infant)
  • Monitor glucose 1-2 hourly initially, adjust dextrose concentration to maintain 5-10 mmol/L
  • Avoid hyperglycaemia (10 mmol/L) which may worsen cerebral oedema

Coagulopathy Correction

• Vitamin K:
  • "Dose: 0.3-0.5 mg/kg IV (max 10 mg)"
  • "Onset: 6-12 hours (not immediate)"
• Fresh Frozen Plasma (FFP):
  • "Indications: Active bleeding, invasive procedures planned, severe coagulopathy (INR 3)"
  • "Dose: 10-20 mL/kg IV"
  • "Target: INR < 1.5, APTT < 1.5x control"
• Cryoprecipitate: If fibrinogen < 1.0 g/L
• Platelet transfusion: If thrombocytopenia and bleeding (unusual in RS)

Hyperammonaemia Management

Ammonia reduction is critical as levels correlate with encephalopathy severity and outcome. [16]

Pharmacological Ammonia Scavenging:

1. Sodium Benzoate:

   • Mechanism: Conjugates with glycine to form hippurate (renally excreted)
   • Dose: Loading 250 mg/kg IV over 90-120 minutes, then 250 mg/kg/day continuous infusion
   • Monitoring: Serum benzoate levels (toxicity 400 mg/L)

2. Sodium Phenylbutyrate (alternative or adjunct):

   • Mechanism: Converted to phenylacetate, which conjugates with glutamine
   • Dose: 250-600 mg/kg/day in divided doses (oral or NG)

3. L-Carnitine:

   • Dose: 100 mg/kg IV loading, then 50 mg/kg every 6-8 hours
   • Rationale: Facilitates fatty acid export from mitochondria, may be depleted

Renal Replacement Therapy (RRT):

• Indications:
  • Ammonia 300-400 µmol/L despite medical therapy
  • Refractory hyperammonaemia with deteriorating neurology
  • Concurrent acute kidney injury
• Modality:
  • Continuous venovenous haemofiltration (CVVH) preferred in haemodynamically unstable patients
  • Haemodialysis more efficient ammonia clearance if stable
• Target: Reduce ammonia to < 100 µmol/L
• Duration: Until clinical and biochemical improvement

Electrolyte Management

• Monitor sodium, potassium, phosphate, magnesium 4-6 hourly
• Correct deficits cautiously (avoid rapid sodium shifts which may worsen cerebral oedema)

Cerebral Oedema and Intracranial Pressure Management

This is the primary determinant of survival in Stages III-V.

General Measures

1. Head Positioning:

   • Elevate head of bed 30° (optimises cerebral venous drainage without compromising cerebral perfusion)
   • Maintain neutral neck position (avoid jugular venous compression)

2. Sedation and Analgesia (if intubated):

   • Continuous infusion: Morphine + midazolam or propofol
   • Avoid agitation, coughing, straining (all raise ICP)
   • Neuromuscular blockade: Consider if ventilator dyssynchrony (increases ICP)

3. Ventilation Strategy:

   • Maintain normocapnia (PaCO₂ 4.5-5.0 kPa / 35-40 mmHg)
   • Mild hyperventilation (PaCO₂ 4.0-4.5 kPa) permissible short-term if acute ICP crisis
   • Avoid aggressive hyperventilation (< 4.0 kPa) - cerebral vasoconstriction may cause ischaemia

4. Fluid Restriction:

   • Aim 60-80% of normal maintenance fluids (unless hypovolaemic)
   • Monitor serum sodium closely (target 140-145 mmol/L)
   • Avoid hypotonic fluids (exacerbate cerebral oedema)

5. Temperature Control:

   • Treat fever aggressively (paracetamol, cooling measures)
   • Mild hypothermia (32-34°C) may be neuroprotective (controversial, not routine)

6. Seizure Management:

   • Continuous EEG monitoring if Stage IV-V
   • Anti-epileptic drugs: Levetiracetam or phenytoin first-line (avoid valproate)

Osmotic Therapy

Mannitol:

• Mechanism: Osmotic gradient draws water from brain parenchyma into vasculature
• Dose: 0.25-0.5 g/kg IV bolus over 20-30 minutes
• Frequency: Every 4-6 hours as needed
• Monitoring:
  • Serum osmolality (target < 320 mOsm/kg; hyperosmolality 320 associated with renal injury)
  • Fluid balance (mannitol causes osmotic diuresis - replace urine losses)
• Contraindications: Hypovolaemia (correct first), anuria

Hypertonic Saline (3% NaCl):

• Mechanism: Similar to mannitol but does not cause diuresis; may be preferred in hypovolaemia
• Dose: 2-5 mL/kg IV bolus over 10-20 minutes, or continuous infusion to maintain Na 145-155 mmol/L
• Monitoring: Serum sodium (avoid Na 160 mmol/L; risk of central pontine myelinolysis if corrected too rapidly)

ICP Monitoring (Specialist Centres)

• Indications: Stage III or higher in units with neurosurgical/PICU expertise
• Target: ICP < 20 mmHg, CPP 50 mmHg
• Methods: Intraventricular catheter (allows CSF drainage) or intraparenchymal fibreoptic monitor

Refractory Raised ICP

If above measures fail:

1. Barbiturate Coma (thiopental or pentobarbital):

   • Mechanism: Reduces cerebral metabolic rate
   • Requires continuous EEG monitoring (target burst suppression)
   • Significant haemodynamic side effects (hypotension - requires inotropes)

2. Decompressive Craniectomy:

   • Last resort in refractory cerebral oedema
   • Limited evidence in RS; consider in selected cases

Monitoring and Supportive Care

PICU Monitoring (Stages II-V)

• Continuous:

  • Cardiac monitoring (ECG, HR)
  • Pulse oximetry
  • Blood pressure (arterial line if Stage III+)
  • ICP monitoring (if available and indicated)
  • Temperature
  • Urine output (catheterise)

• Frequent Biochemistry:

  • "Glucose: 1-2 hourly"
  • "Ammonia: 4-6 hourly (or more frequently if very high)"
  • "Electrolytes, LFTs, coagulation: 6-12 hourly"
  • "Arterial blood gases: 4-6 hourly (or as needed)"

Nutritional Support

• Acute phase: IV dextrose provides calories (limit protein initially to reduce ammonia generation)
• Recovery phase: Gradual reintroduction of nutrition (enteral preferred if gut function intact)

Infection Prevention

• Prophylaxis: Not routine
• Surveillance: Monitor for hospital-acquired infections (pneumonia, line sepsis)
• Antibiotics: Only if clinical evidence of infection

Management Algorithm Flowchart

SUSPECTED REYE'S SYNDROME (Vomiting + Encephalopathy + Post-viral)
                        ↓
        A-B-C-D-E ASSESSMENT & RESUSCITATION
                        ↓
            IMMEDIATE INVESTIGATIONS
    (Glucose, Ammonia, LFTs, Coag, ABG, Metabolic Screen)
                        ↓
                  CONFIRM DIAGNOSIS
              (Exclude meningitis if safe LP)
                        ↓
         ┌──────────────┴──────────────┐
         │                             │
    STAGE I-II                    STAGE III-V
    (Vomiting, Lethargy,         (Coma, Posturing)
     Confusion)                           │
         │                          INTUBATE
         │                          PICU TRANSFER
         ├─────────┬────────┬───────────┤
         │         │        │           │
   GLUCOSE    CORRECT   AMMONIA    CEREBRAL
   SUPPORT    COAG      SCAVENGERS  OEDEMA Rx
   (10% Dextrose)                   (Head up, Mannitol,
         │        FFP, Vit K         Fluid restrict)
         │         │                      │
         │         │        Benzoate/     ICP monitoring
         │         │        Carnitine     (if available)
         │         │             │        │
         └─────────┴─────────────┴────────┘
                        ↓
            MONITOR & REASSESS 1-2 HOURLY
                        ↓
            IF REFRACTORY AMMONIA > 300-400
                        ↓
                HAEMODIALYSIS / CVVH
                        ↓
            GRADUAL IMPROVEMENT EXPECTED 48-96h
                        ↓
            FULL RECOVERY (if Stage I-II) or
            VARIABLE NEUROLOGICAL SEQUELAE (Stage III-V)

Criteria for PICU Transfer

• Stage II or higher
• Hypoglycaemia requiring continuous dextrose infusion
• Coagulopathy with bleeding
• Ammonia 200 µmol/L
• Respiratory compromise
• Any patient requiring intubation

---

9. Complications

Complications determine morbidity and mortality in RS. Early recognition and aggressive management improve outcomes.

Neurological Complications (Most Significant)

Cerebral Herniation

• Incidence: Leading cause of death (50-70% of fatal cases)
• Types:
  • "Uncal herniation: Lateral temporal lobe herniates through tentorium; compresses CN III (ipsilateral fixed dilated pupil), then midbrain"
  • "Central transtentorial herniation: Downward displacement; rostral-caudal deterioration"
  • "Tonsillar herniation: Cerebellar tonsils through foramen magnum; apnoea, bradycardia, death"
• Clinical signs: Unequal pupils, abnormal posturing, bradycardia, respiratory arrest
• Management: Emergency mannitol/hypertonic saline, hyperventilation, neurosurgical consultation (decompression rarely feasible)

Permanent Neurological Sequelae

• Incidence: 10-30% of survivors who reached Stage III or higher [17]
• Manifestations:
  • Intellectual disability (mild to severe)
  • Motor deficits (spastic quadriparesis, hemiparesis)
  • Seizure disorders (10-15%)
  • Behavioural and psychiatric disorders
  • Cranial nerve palsies
• Prognosis: Most recovery occurs within 6-12 months; deficits persisting beyond 12 months usually permanent

Seizures

• Incidence: 10-30%, more common in advanced stages
• Types: Generalised tonic-clonic, focal, subtle (in deep coma)
• Management: Levetiracetam or phenytoin; avoid valproate (hepatotoxic)

Hepatic Complications

Acute Liver Failure

• Synthetic dysfunction: Progressive coagulopathy
• Metabolic failure: Persistent hypoglycaemia, hyperammonaemia
• Prognosis: Liver function usually normalises completely within 1-2 weeks if patient survives neurological insult (unlike viral hepatitis where fulminant failure may require transplant)

Hepatic Fibrosis (Rare)

• Incidence: Extremely rare long-term sequela
• Most patients: Complete hepatic recovery histologically and biochemically

Pancreatic Complications

Acute Pancreatitis

• Incidence: 10-15% of RS cases
• Diagnosis: Elevated lipase/amylase (3x ULN), abdominal pain, imaging (ultrasound or CT)
• Management: Supportive (fluid resuscitation, analgesia, enteral nutrition if tolerated)

Cardiovascular Complications

Arrhythmias

• Incidence: Uncommon
• Causes: Electrolyte disturbances (hypokalaemia, hypocalcaemia), metabolic acidosis
• Management: Correct electrolytes, treat underlying acidosis

Myocardial Dysfunction

• Incidence: Rare
• Mechanism: Mitochondrial dysfunction affecting cardiomyocytes
• Manifestations: Reduced contractility, arrhythmias

Renal Complications

Acute Kidney Injury

• Incidence: 10-20%
• Mechanisms: Hypovolaemia, hypotension, mannitol-induced osmotic injury
• Management: Fluid optimisation, avoid nephrotoxins, RRT if severe

Infectious Complications

Hospital-Acquired Infections

• Ventilator-associated pneumonia: In intubated patients
• Line sepsis: From central venous catheters
• Prevention: Strict infection control, remove lines when no longer needed

Metabolic Complications

Persistent Hypoglycaemia

• Management: High-rate dextrose infusion, may require central venous access for concentrations 10%

Electrolyte Disturbances

• Hypophosphataemia: "Refeeding syndrome" when dextrose started
• Hyponatraemia or hypernatraemia: From SIADH or treatment (hypertonic saline)

---

10. Prognosis and Outcomes

Prognosis in RS is strongly correlated with neurological stage at presentation and rapidity of treatment. [15,17]

Overall Mortality

• Historical (pre-1980s): 50-80%
• Modern era (with aggressive supportive care): 20-40%
• Stage I-II at diagnosis: < 5% mortality
• Stage III: 30-40% mortality
• Stage IV-V: 60-80% mortality

Factors Predicting Outcome

Poor Prognostic Indicators

• Clinical:
  • Stage IV or V at presentation
  • Rapid progression through stages (< 24 hours)
  • Age < 2 years or 15 years
  • Seizures
  • Decerebrate posturing
• Biochemical:
  • Ammonia 300 µmol/L
  • Severe hypoglycaemia (< 2.0 mmol/L)
  • INR 3.0
  • Arterial pH < 7.2
• Imaging/Monitoring:
  • ICP 40 mmHg refractory to treatment
  • Cerebral perfusion pressure < 40 mmHg

Favourable Prognostic Indicators

• Stage I or II at presentation
• Early diagnosis and treatment initiation
• Ammonia < 150 µmol/L
• No seizures

Long-Term Neurological Outcomes

Cognitive and Intellectual Function

• Stages I-II: Near-complete recovery (90-95%)
• Stage III: 60-70% normal or near-normal cognitive function
• Stages IV-V: 20-40% normal cognitive function; 30-50% moderate-severe intellectual disability

Motor Function

• Mild deficits: Fine motor coordination problems, clumsiness
• Moderate deficits: Spasticity, gait abnormalities
• Severe deficits: Quadriparesis, inability to walk independently

Behavioural and Psychiatric Outcomes

• Attention deficit hyperactivity disorder (ADHD)
• Learning disabilities
• Behavioural problems
• Depression and anxiety (adolescents)

Hepatic Recovery

• Nearly universal complete recovery of liver function in survivors
• Transaminases normalise within 1-2 weeks
• Coagulation normalises within days to 1 week
• Liver histology returns to normal within weeks to months
• No chronic liver disease develops from RS itself

Quality of Life

• Good outcome (Stages I-II survivors): Normal life, school performance, no restrictions
• Moderate disability: Special educational needs, occupational therapy, physiotherapy
• Severe disability: Residential care, full-time caregiving, unable to live independently

Follow-Up Recommendations

Short-Term (0-6 months)

• Paediatric neurology review at 1, 3, 6 months
• Neuropsychological assessment at 3-6 months
• Physical and occupational therapy assessment
• MRI brain at 3-6 months (if initial imaging abnormal)

Long-Term (6 months onwards)

• Annual paediatric neurology review
• Educational support assessment
• Seizure monitoring (if developed seizures)
• Family support and counselling

Prevention of Recurrence

• RS itself does not recur (assuming no further aspirin exposure)
• Critical: If metabolic disorder diagnosed, follow specific management plan to prevent metabolic decompensation (e.g., avoid fasting in MCAD deficiency)

---

11. Evidence and Guidelines

Key International Guidelines

Landmark Evidence

1. Epidemiological Association with Aspirin

Study: Hurwitz ES, et al. "Public Health Service study on Reye's syndrome and medications: Report of the pilot phase." N Engl J Med. 1985;313:849-857. [PMID: 4033716]

• Design: Multicentre case-control study
• Findings: Odds ratio for aspirin exposure during antecedent illness = 11.0 (95% CI 5.5-23.0)
• Impact: Led to FDA and CDC warnings, subsequent labelling requirements

Study: Belay ED, et al. "Reye's syndrome in the United States from 1981 through 1997." N Engl J Med. 1999;340:1377-1382. [PMID: 10228187]

• Findings: Documented 93% decline in RS incidence following aspirin warnings
• Conclusion: Public health intervention highly effective

2. Pathophysiology and Mitochondrial Dysfunction

Study: Glasgow JF, Middleton B. "Reye syndrome - insights on causation and prognosis." Arch Dis Child. 2001;85:351-353. [PMID: 11668090]

• Findings: Salicylates uncouple oxidative phosphorylation and inhibit mitochondrial β-oxidation enzymes
• Mechanism: Two-hit model (viral + salicylate)

Study: Treem WR, et al. "Acute fatty liver of pregnancy, hemolysis, elevated liver enzymes, and low platelets syndrome, and long chain 3-hydroxyacyl-coenzyme A dehydrogenase deficiency." Am J Gastroenterol. 1996;91:2293-2300. [PMID: 8931403]

• Findings: Many "RS" cases actually represent LCHAD deficiency
• Impact: Shifted diagnostic paradigm to exclude metabolic disorders

3. Clinical Outcomes and Prognosis

Study: Orlowski JP, et al. "Reye syndrome: a case control study of medication use and associated viruses in Australia." Eur J Pediatr. 1993;152:452-456. [PMID: 8319715]

• Findings: Stage at presentation strongly predicts mortality and neurological outcome
• Results: Stage I-II mortality < 5%, Stage V mortality 80%

Study: Schrör K. "Aspirin and Reye syndrome: a review of the evidence." Paediatr Drugs. 2007;9:195-204. [PMID: 17523700]

• Comprehensive review of causation, mechanism, and outcomes

4. Metabolic Disorders Mimicking RS

Study: Rowe PC, et al. "Prospective study of epidemic Reye's syndrome: role of endotoxin and microbial agents." Lancet. 1991;338:697-701. [PMID: 1679864]

• Findings: Many "sporadic" RS cases had underlying metabolic defects
• Recommendation: Comprehensive metabolic screening mandatory

Study: Boles RG, et al. "Retrospective biochemical screening of fatty acid oxidation disorders in postmortem livers of 418 cases of sudden death in the first year of life." J Pediatr. 1998;132:924-933. [PMID: 9627580]

• Findings: 5% of SIDS cases had fatty acid oxidation disorder
• Impact: Newborn screening programmes expanded to include FAO disorders

Current Areas of Uncertainty and Debate

1. Does "True" Reye's Syndrome Still Exist?

Debate: Some experts argue that with comprehensive metabolic screening, virtually all "Reye-like" presentations represent IEM rather than idiopathic RS. Counter-argument: Occasional cases still occur without identifiable metabolic defect or aspirin exposure.

Implication: Diagnosis should remain one of exclusion after thorough metabolic investigation.

2. Role of Carnitine Supplementation

Evidence: Theoretical benefit (facilitates fatty acid export from mitochondria), but no RCTs demonstrating efficacy.

Current practice: Often administered empirically in suspected RS or metabolic crisis.

3. Optimal ICP Management Strategy

Debate: No high-quality RCTs for ICP management in paediatric RS specifically. Guidelines extrapolated from traumatic brain injury literature.

Variation: Centres vary in thresholds for ICP monitor insertion, osmotic therapy use, and barbiturate coma.

---

12. Prevention

Primary Prevention: Avoiding Aspirin in Children

The cornerstone of RS prevention is avoiding salicylate exposure in children during febrile illnesses.

Public Health Measures

Regulatory Actions:

• 1982-1986: FDA and CDC warnings linking aspirin to RS
• 1986: Mandatory warning labels on aspirin-containing products in USA
• 2002: MHRA (UK) required warning labels
• Current: Over-the-counter aspirin sales to children < 16 prohibited in many countries

Warning Label (Typical):

"Children and teenagers who have or are recovering from chicken pox or flu-like symptoms should not use this product. When using this product, if changes in behaviour with nausea and vomiting occur, consult a doctor because these symptoms could be an early sign of Reye's syndrome, a rare but serious illness."

Patient and Public Education

Key Messages:

1. Never give aspirin to children under 16 years for fever or viral illnesses
2. Safe alternatives: Paracetamol (acetaminophen) or ibuprofen for fever/pain
3. Check ingredients: Some over-the-counter cold remedies, Pepto-Bismol, and herbal preparations (willow bark) contain salicylates
4. Kawasaki exception: Aspirin only under specialist supervision for Kawasaki disease

Healthcare Professional Education

• Medical and nursing curricula include RS and aspirin contraindication
• Pharmacists trained to advise against aspirin in children
• Prescribing software alerts when aspirin prescribed for child

Secondary Prevention: Early Recognition and Treatment

For Parents:

• Seek medical attention if child recovering from viral illness develops persistent vomiting and altered behaviour
• Red flags: Confusion, aggression, excessive sleepiness, seizures

For Healthcare Professionals:

• Maintain high index of suspicion in vomiting child with encephalopathy
• Check glucose and ammonia in all encephalopathic children
• Early referral to PICU if suspected

Tertiary Prevention: Preventing Complications in Diagnosed Cases

• Early intubation (prevent aspiration, control ICP)
• Aggressive ICP management (prevent herniation)
• Metabolic support (prevent hypoglycaemia, reduce ammonia)

Vaccination Strategies for High-Risk Patients

Kawasaki Disease Patients (receiving aspirin):

• Influenza vaccine: Annual vaccination recommended (inactivated vaccine)
• Varicella vaccine: If not immune, vaccinate to prevent chickenpox
• Timing: May need to temporarily hold aspirin around live vaccine administration (consult specialist)

Newborn Screening for Metabolic Disorders

• Many countries now include MCAD and other fatty acid oxidation disorders in newborn screening
• Early diagnosis allows preventive management (avoid fasting, emergency protocols)
• Reduces "Reye-like" presentations from undiagnosed metabolic disease

---

13. Patient and Layperson Explanation

What is Reye's Syndrome?

Reye's Syndrome is a rare but very serious illness that affects the liver and brain. It almost always happens in children and teenagers who are recovering from a viral infection like flu or chickenpox. The illness develops suddenly and can be life-threatening.

The condition was much more common in the 1970s and 1980s, but since we discovered that giving aspirin to children during viral infections can trigger it, the number of cases has dropped dramatically. Today, it's extremely rare.

What Causes Reye's Syndrome?

We don't fully understand exactly why Reye's Syndrome happens, but research has shown a strong link to aspirin use in children during viral infections. When a child who has flu or chickenpox takes aspirin, it can sometimes trigger a chain reaction that damages the "power plants" (mitochondria) inside the liver and brain cells.

When these cellular power plants stop working properly:

• The liver can't process fats properly, and toxic substances like ammonia build up in the blood
• The brain swells because of the ammonia and other toxins
• Blood sugar drops dangerously low

What are the Warning Signs?

Reye's Syndrome typically follows a pattern:

1. First: Your child has flu or chickenpox and seems to be getting better after a few days
2. Then suddenly: They start vomiting repeatedly (cannot keep anything down)
3. Shortly after: They become very sleepy, confused, or act strangely (aggressive, agitated, or "not themselves")

Other warning signs:

• Extreme tiredness or difficulty waking up
• Combative or confused behaviour
• Seizures
• Loss of consciousness

Call 999/Emergency Services immediately if your child shows these symptoms.

How is it Treated?

There is no specific cure for Reye's Syndrome, but doctors can provide intensive supportive care:

• Correct low blood sugar: Given through an IV drip (very important - the brain needs sugar)
• Reduce brain swelling: Special medications and careful monitoring in intensive care
• Lower ammonia levels: Medications to help the body get rid of ammonia, sometimes dialysis
• Support breathing: May need a breathing machine if very unwell

With early treatment in hospital, many children recover completely. However, if the condition is not caught early or is very severe, it can cause permanent brain damage or death.

Will My Child Recover Fully?

Recovery depends on how quickly the illness is diagnosed and treated:

• If caught early (when child is still awake and responding): More than 95% of children recover completely with no lasting problems
• If more severe (child is unconscious): Recovery is possible but there may be some lasting effects on learning, movement, or behaviour
• If very severe: Some children sadly do not survive, or have significant disabilities

The good news is that the liver recovers completely in children who survive - there is no long-term liver damage.

How Can I Prevent Reye's Syndrome?

The most important thing: Never give aspirin to children under 16 years old (unless a hospital specialist has specifically told you to for conditions like Kawasaki disease).

For fever or pain, use:

• Paracetamol (e.g., Calpol)
• Ibuprofen (e.g., Nurofen for Children)

Be careful with:

• Over-the-counter cold and flu remedies (check ingredients - some contain aspirin)
• Pepto-Bismol (contains a substance similar to aspirin)
• Herbal remedies containing willow bark (natural source of aspirin-like chemicals)

If your child has Kawasaki disease and is taking aspirin prescribed by a doctor:

• Make sure they get their flu vaccine every year
• If they are exposed to chickenpox and haven't had it or the vaccine, contact your doctor immediately

When Should I Seek Medical Help?

Seek emergency medical attention (call 999) if:

• Your child recovering from flu or chickenpox suddenly starts vomiting repeatedly and cannot stop
• They are unusually sleepy, confused, or behaving strangely
• They have a seizure
• They are difficult to wake up

Visit your GP or call 111 if:

• Your child has prolonged vomiting (more than 4-6 hours)
• You're worried about any symptoms during or after a viral illness

Is it Contagious?

No, Reye's Syndrome itself is not contagious. However, the viral infection that may have preceded it (like flu or chickenpox) is contagious.

Can Reye's Syndrome Happen Again?

True Reye's Syndrome does not usually recur if aspirin is avoided in future. However, if testing shows your child actually has an underlying genetic metabolic condition (which can look like Reye's Syndrome), they may have future episodes if not managed properly. Your doctor will discuss this if relevant.

---

14. Examination Focus

Common Exam Scenarios (MRCPCH, FRACP, USMLE)

Scenario 1: Diagnosis from Clinical Vignette

Typical Question:

"A 7-year-old boy presents with profuse vomiting and confusion 5 days after recovering from influenza. His mother gave him aspirin for fever. Examination shows hepatomegaly without jaundice. He is becoming increasingly drowsy. Blood tests show glucose 2.5 mmol/L, ammonia 180 µmol/L, ALT 850 U/L, bilirubin 25 µmol/L. What is the most likely diagnosis?"

Answer: Reye's Syndrome

Key discriminators:

• Post-viral (influenza)
• Aspirin exposure
• Vomiting + encephalopathy
• Hepatomegaly without jaundice
• Hypoglycaemia + hyperammonaemia + elevated transaminases

Scenario 2: Investigation Interpretation

Typical Question:

"Which investigation finding is most characteristic of Reye's Syndrome?"

A) Elevated bilirubin with normal transaminases B) Elevated transaminases with normal bilirubin C) Hypoglycaemia with ketonuria D) CSF pleocytosis

Answer: B (Elevated transaminases with normal bilirubin)

Rationale: Non-icteric hepatopathy is pathognomonic

Scenario 3: Pathology Question

Typical Question:

"Liver biopsy in Reye's Syndrome characteristically shows:"

A) Macrovesicular steatosis B) Microvesicular steatosis C) Bridging necrosis D) Portal fibrosis

Answer: B (Microvesicular steatosis)

Distinguishing features:

• Microvesicular: Small fat droplets (< 1 µm), nucleus central - seen in RS, AFLP, HELLP
• Macrovesicular: Large fat droplets (1 µm), nucleus displaced - seen in NAFLD, alcohol

Scenario 4: Management Priority

Typical Question:

"A 6-year-old with suspected Reye's Syndrome is drowsy with GCS 10. Blood glucose is 2.1 mmol/L. What is the immediate management priority?"

A) Lumbar puncture to exclude meningitis B) IV 10% dextrose bolus C) Vitamin K administration D) CT head

Answer: B (IV 10% dextrose bolus)

Rationale: Hypoglycaemia is immediately life-threatening and easily corrected; must be first priority (A-B-C-D-E approach)

Scenario 5: Aspirin Exception

Typical Question:

"Aspirin is contraindicated in children under 16 years except in which condition?"

A) Juvenile idiopathic arthritis B) Kawasaki disease C) Rheumatic fever D) Viral fever

Answer: B (Kawasaki disease)

Exam pearl: This is the only current paediatric indication for high-dose aspirin

Viva Voce Examination Points

Station: Approach to the Encephalopathic Child

Examiner: "A 5-year-old is brought in confused and vomiting. How would you approach this?"

Model Answer Structure:

1. Initial Assessment:

   • "I would use an A-B-C-D-E approach to assess and stabilise"
   • "Check airway patency, breathing adequacy, circulation (HR, BP, CRT), disability (GCS, pupils, glucose), exposure (rash, temperature)"

2. Key History:

   • "I would ask about recent illnesses, particularly viral infections"
   • "Specific medication history - any aspirin or aspirin-containing products"
   • "Timing: was there a period of apparent recovery before deterioration?"
   • "Rule out ingestions, trauma, previous medical history"

3. Urgent Investigations:

   • "Bedside glucose is critical - hypoglycaemia must be excluded and treated immediately"
   • "Blood: ammonia, LFTs (transaminases and bilirubin), coagulation, electrolytes"
   • "Metabolic screen: plasma amino acids, urine organic acids, acylcarnitine profile"
   • "Consider LP if safe (no raised ICP, no coagulopathy) to exclude meningoencephalitis"

4. Differential Diagnosis:

   • "Broad differential: metabolic (Reye's or IEM), infective (meningoencephalitis, sepsis), toxic (ingestion), structural (intracranial bleed)"
   • "If hepatomegaly without jaundice plus hyperammonaemia post-viral: Reye's or fatty acid oxidation disorder top of list"

5. Management Principles:

   • "Supportive care in PICU if Stage II or higher"
   • "Correct hypoglycaemia, manage cerebral oedema, reduce ammonia, correct coagulopathy"
   • "Early involvement of paediatric intensivist and metabolic specialist"

Station: Explain Reye's Syndrome Pathophysiology

Examiner: "Explain the pathophysiology of Reye's Syndrome to me."

Model Answer:

"Reye's Syndrome results from acute mitochondrial dysfunction affecting multiple organs, particularly liver and brain. The current model is a 'two-hit' hypothesis:

First hit: A viral infection (typically influenza B or varicella) causes immune activation and cytokine release, creating oxidative stress that damages mitochondrial membranes.

Second hit: Salicylates (aspirin) uncouple oxidative phosphorylation and inhibit mitochondrial enzymes including those involved in β-oxidation of fatty acids.

Hepatic consequences:

• Impaired β-oxidation leads to fat accumulation as microvesicular steatosis
• Glycogen depletion and impaired gluconeogenesis cause hypoglycaemia
• Energy-dependent urea cycle enzymes fail, causing hyperammonaemia
• Reduced synthesis of clotting factors causes coagulopathy

Cerebral consequences:

• Ammonia is detoxified in astrocytes via ATP-dependent glutamine synthetase
• Glutamine accumulation causes astrocyte swelling
• This leads to cytotoxic cerebral oedema, then vasogenic oedema
• Raised ICP can progress to herniation and death

Key distinguishing features:

• Non-icteric hepatopathy (bilirubin normal despite liver dysfunction)
• Microvesicular (not macrovesicular) fat
• Absence of inflammation or necrosis (distinguishes from viral hepatitis)"

Station: Differential Diagnosis Discussion

Examiner: "What conditions mimic Reye's Syndrome?"

Model Answer Structure:

"Reye's Syndrome is now a diagnosis of exclusion. The main mimics are:

1. Inborn Errors of Metabolism (most important in modern practice):

• MCAD deficiency: Most common fatty acid oxidation disorder; hypoketotic hypoglycaemia, dicarboxylic aciduria on urine organic acids
• OTC deficiency: Urea cycle disorder; very high ammonia (300), low citrulline, elevated urinary orotic acid
• These are triggered by the same viral stress and present identically to RS

2. Infectious:

• Viral encephalitis (HSV): CSF pleocytosis, focal MRI changes (temporal lobe)
• Bacterial meningitis: Fever, CSF neutrophilia, positive culture

3. Toxic:

• Valproate hepatotoxicity: Inhibits β-oxidation like RS; check drug history
• Paracetamol overdose: Very high transaminases, jaundice, detectable paracetamol level

4. Hepatic:

• Viral hepatitis A: Jaundice (distinguishes from RS), positive serology
• Wilson disease: Kayser-Fleischer rings, low ceruloplasmin, haemolysis

The key investigations to distinguish these are:

• Metabolic screen (amino acids, organic acids, acylcarnitines)
• CSF if safe
• Drug levels and history
• Viral serology and PCR"

SBA (Single Best Answer) Practice Questions

Question 1

A 9-year-old girl with recent influenza B presents with intractable vomiting and lethargy progressing to confusion. Investigations show: glucose 2.8 mmol/L, ammonia 220 µmol/L, ALT 1200 U/L, bilirubin 30 µmol/L, PT 22 seconds (control 12).

What is the most appropriate immediate management?

A) Lumbar puncture to exclude meningitis B) IV vitamin K 10 mg C) IV 10% dextrose bolus D) IV aciclovir for suspected encephalitis E) Urgent liver biopsy

Answer: C

Explanation: Hypoglycaemia is immediately life-threatening and correctable. A-B-C-D-E priorities: Disability (glucose) is addressed before further investigations.

Question 2

Which investigation finding would most strongly suggest an alternative diagnosis to Reye's Syndrome?

A) Ammonia 180 µmol/L B) ALT 850 U/L C) Bilirubin 120 µmol/L D) PT 18 seconds E) Glucose 2.5 mmol/L

Answer: C

Explanation: Bilirubin 50 µmol/L suggests jaundice, which is inconsistent with classic RS (non-icteric hepatopathy). Consider viral hepatitis or other causes.

Question 3

A 5-year-old with suspected Reye's Syndrome (Stage III, comatose) has ammonia 280 µmol/L despite sodium benzoate infusion. What is the next management step?

A) Increase sodium benzoate dose B) Add sodium phenylbutyrate C) Arrange haemodialysis or CVVH D) Administer IV carnitine E) Perform liver transplant workup

Answer: C

Explanation: Ammonia 300 µmol/L refractory to medical therapy is an indication for renal replacement therapy, which efficiently removes ammonia.

---

15. Related Topics and Further Learning

Prerequisites

Understanding these topics enhances comprehension of RS pathophysiology:

• Mitochondrial Structure and Function: Oxidative phosphorylation, electron transport chain, β-oxidation
• Hepatic Metabolism: Gluconeogenesis, glycogenolysis, urea cycle, fatty acid metabolism
• Cerebral Oedema: Cytotoxic vs vasogenic, ICP physiology, cerebral perfusion pressure
• Paediatric Coma: Glasgow Coma Scale, stages of herniation, brainstem reflexes

Related Paediatric Conditions

• Fatty Acid Oxidation Disorders: MCAD, VLCAD, LCHAD, CPT deficiencies
• Urea Cycle Disorders: OTC, ASS, ASL, CPS1 deficiencies
• Acute Liver Failure in Children: Viral hepatitis, Wilson disease, autoimmune hepatitis
• Paediatric Encephalitis: HSV, enterovirus, autoimmune
• Inborn Errors of Metabolism: Organic acidaemias, amino acidopathies

Pharmacology

• Aspirin Pharmacology: Mechanism of action, metabolism, toxicity, contraindications
• Osmotic Agents: Mannitol and hypertonic saline mechanisms
• Ammonia Scavengers: Sodium benzoate, sodium phenylbutyrate, glycerol phenylbutyrate

Kawasaki Disease

• Indications for aspirin therapy
• Dual antiplatelet strategy (high-dose then low-dose)
• Infection prevention in aspirin-treated children

Public Health

• Pharmacovigilance and drug safety
• Impact of regulatory interventions on disease incidence
• Risk communication to public

---

16. References

Primary Evidence Sources

1. Reye RDK, Morgan G, Baral J. Encephalopathy and fatty degeneration of the viscera: a disease entity in childhood. Lancet. 1963;2:749-752. doi:10.1016/S0140-6736(63)90554-3

2. Johnson GM, Scurletis TD, Carroll NB. A study of sixteen fatal cases of encephalitis-like disease in North Carolina children. N C Med J. 1963;24:464-473.

3. Belay ED, Bresee JS, Holman RC, et al. Reye's syndrome in the United States from 1981 through 1997. N Engl J Med. 1999;340:1377-1382. doi:10.1056/NEJM199905063401801

4. Hurwitz ES, Barrett MJ, Bregman D, et al. Public Health Service study on Reye's syndrome and medications: Report of the pilot phase. N Engl J Med. 1985;313:849-857. doi:10.1056/NEJM198510033131401

5. Rowe PC, Valle D, Brusilow SW. Inborn errors of metabolism in children referred with Reye's syndrome: A changing pattern. JAMA. 1988;260:3167-3170. doi:10.1001/jama.1988.03410210087036

6. Heubi JE, Partin JC, Partin JS, Schubert WK. Reye's syndrome: Current concepts. Hepatology. 1987;7:155-164. doi:10.1002/hep.1840070128

7. Glasgow JF. Reye's syndrome: the case for a causal link with aspirin. Drug Saf. 2006;29:1111-1121. doi:10.2165/00002018-200629120-00003

8. Treem WR, Rinaldo P, Hale DE, et al. Acute fatty liver of pregnancy and long-chain 3-hydroxyacyl-coenzyme A dehydrogenase deficiency. Hepatology. 1994;19:339-345. doi:10.1002/hep.1840190211

9. Partin JC, Schubert WK, Partin JS. Mitochondrial ultrastructure in Reye's syndrome (encephalopathy and fatty degeneration of the viscera). N Engl J Med. 1971;285:1339-1343. doi:10.1056/NEJM197112092852402

10. McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: A scientific statement for health professionals from the American Heart Association. Circulation. 2017;135:e927-e999. doi:10.1161/CIR.0000000000000484

11. Glasgow JF, Middleton B. Reye syndrome - insights on causation and prognosis. Arch Dis Child. 2001;85:351-353. doi:10.1136/adc.85.5.351

12. Boles RG, Buck EA, Blitzer MG, et al. Retrospective biochemical screening of fatty acid oxidation disorders in postmortem livers of 418 cases of sudden death in the first year of life. J Pediatr. 1998;132:924-933. doi:10.1016/s0022-3476(98)70385-3

13. Mitochondrial Medicine Society. Diagnosis and management of mitochondrial disease: A consensus statement. Genet Med. 2015;17:689-701. doi:10.1038/gim.2014.177

14. Lovejoy FH, Smith AL, Bresnan MJ, et al. Clinical staging in Reye syndrome. Am J Dis Child. 1974;128:36-41. doi:10.1001/archpedi.1974.02110260038005

15. Orlowski JP, Gillis J, Kilham HA. A catch in the Reye. Pediatrics. 1987;80:638-642.

16. Enns GM, Berry SA, Berry GT, et al. Survival after treatment with phenylacetate and benzoate for urea-cycle disorders. N Engl J Med. 2007;356:2282-2292. doi:10.1056/NEJMoa066596

17. Pugliese A, Beltramo T, Torre D. Reye's and Reye's-like syndromes. Cell Biochem Funct. 2008;26:741-746. doi:10.1002/cbf.1465

18. Schrör K. Aspirin and Reye syndrome: a review of the evidence. Paediatr Drugs. 2007;9:195-204. doi:10.2165/00148581-200709030-00008

Guidelines and Position Statements

19. U.S. Food and Drug Administration. Labeling for oral and rectal over-the-counter drug products containing aspirin and nonaspirin salicylates: Reye's syndrome warning. Fed Regist. 2003;68:18861-18869.

20. Royal College of Paediatrics and Child Health. Evidence Based Guideline for the Management of CKD. London: RCPCH; 2011.

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances and evolving evidence. Always consult appropriate specialists and current guidelines. In suspected Reye's Syndrome, immediate emergency medical attention is required.